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Syphilis is a multistage, sexually transmitted disease caused by the spirochete, Treponema pallidum (Tp). A significantly high 
incidence of syphilis has been reported in several countries, including China, and there is an urgent need for the development 
of efficacious vaccines against syphilis. DNA vaccines are a major breakthrough in the field of vaccination with several   
advantages over traditional vaccines. Animal model studies of Tp DNA vaccines have not been reported elsewhere but our 
previous reports describe the development of a single-gene Tp DNA vaccine and preclinical immunization study. In this study, 
chitosan (CS) nanoparticles were used as a vector and an interleukin-2 expression plasmid (pIL-2) as an adjuvant to enhance a 
TpGpd DNA vaccine candidate (pTpGpd) in a rabbit Tp skin challenge model. At week 8 after the first immunization, three 
rabbits from each group were used to determine cytokine measurements and spleen lymphocyte proliferation assay. pTpGpd in 
combination with pIL-2 wrapped with CS led to the greatest enhancement of anti-TpGpd antibodies and T-cell proliferation. 
During infection, levels of anti-TpGpd antibodies and T-cell proliferation were measured. Both the serum special IgG and IL-2, 
interferon- were significantly increased by the co-injection of the IL-2 plasmid compared with the injection of TpGpd DNA 
alone (P<0.05). Furthermore, IL-2 plasmid coinjection efficiently enhanced the antigen-specific lymphocyte proliferation re-
sponse. Additionally, the ratios of positive skin lesions and ulcer lesions in groups immunized with pTpGpd were significantly 
lower than those of the pIL-2, CS or pIL-2 mixed with CS control groups (P<0.001). CS vectored and pIL-2 adjuvanted 
pTpGpd immunized animals exhibited the lowest rates of positive skin tests (8.33%) and ulcer lesions (4.17%) and the fastest 
recovery (42 d). These experiments indicate that co-injection of a pIL-2 plasmid with pTpGpd DNA vaccine wrapped with CS 
can significantly strengthen the long-term stability of immune response during infection, efficiently improve the protective ef-
fect against T. pallidum spirochetes infection and attenuate syphilitic lesion development.  
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Transduction efficiency affects DNA vaccine delivery in the immunization process and has a large bearing on dosage. 
Chitosan (CS) is a natural polysaccharide derived from the 
deacetylation of chitin. Given the high number of positively 
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charged amino acids, CS possesses unique polycationic 
characteristics and easily combines with DNA. CS protects 
the DNA from intracellular nuclease degradation and asso-
ciates with the cell membrane for easier transport into the 
cell. Exogenous gene transfection efficiency and expression 
of DNA in mammalian cells are significantly improved 
when coadministered with CS [1,2]. As a new, efficient type 
of gene transduction vectors, nanoparticles are becoming 
increasingly popular and it has been widely shown that CS 
nanoparticles effectively enhance the immune effects of 
DNA vaccines in mice [3–5].  
Cytokines play important roles in regulation of the im-
mune responses and inflammation. Intramuscular injection 
of cytokine expression vectors can significantly regulate the 
immune response [6–8]. Barouch et al. [9] co-injected an 
interleukin (IL)-2 expression plasmid together with HIV-1 
DNA vaccines into rhesus macaques and found that IL-2 
induced much higher levels of antibody and cytotoxic lym-
phocyte (CTL) activity, when compared with the DNA vac-
cine alone. 
Therefore, based on preliminary protection studies of 
New Zealand rabbits immunized with recombinant 
pcDNA3.1/Tp92 and pcDNA3.1/IL-2 (pIL-2) [10], the cur-
rent study investigated the additional protective effects of 
using CS for vaccination. In this study, a Treponema pal-
lidum (Tp) membrane protein Gpd expression plasmid, 
pcDNA3.1/TpGpd (pTpGpd), was coadministered with a 
cytokine adjuvant, pIL-2, and CS nanoparticles. This study 
aims to explore the pTpGpd DNA vaccine-induced immune 
response before and after Tp infection in rabbit skin, with 
the use of the targeting and slow release of CS nanoparticles 
and adjuvant effect of pIL-2. Further, this study evaluated 
the adjuvant effect of CS nanoparticles and pIL-2 for the 
eventual establishment of a highly active anti-Tp response 
in animal models with the hope for a human syphilis vac-
cine. 
1  Materials and methods 
1.1  Rabbits  
Adult New Zealand White rabbits were obtained from the 
Department of Laboratory Animals, University of South 
China (Hengyang, China). All animal experiments were 
approved by the governing Animal Welfare Committee and 
conducted in accordance with the regulations of the institu-
tion. Rabbits were individually housed at 18–20°C and given 
antibiotic-free food and water.  
1.2  Bacteria strains, DNA plasmids and reagents 
The Tp Nichols strain was a gift from Dr. Gu WeiMing 
(Shanghai Skin Disease and Sexual Disease Hospital) and 
was stored at the Pathogenic Biology Institute at University 
of South China (Hengyang, China). Escherichia coli JM109 
and syphilis standard serum were obtained from the Patho-
genic Biology Institute (Hengyang, China). The two DNA 
plasmids pTpGpd, encoding the TpGpd protein, and pIL-2, 
the IL-2 expression plasmid, were constructed and identi-
fied in our laboratory, as described previously [10,11]. 
HRP-labeled goat anti-human/rabbit IgG secondary antibody 
was purchased from Invitrogen (Shanghai, China). Rabbit 
interferon (IFN)-γ and IL-2 enzyme-linked immunosorbent 
assay (ELISA) detection kits were purchased from Shanghai 
Jianglai Biological Technology (Shanghai, China). Fetal 
bovine serum (FBS) and RPMI-1640 medium were pur-
chased from the HyClone Company (Logan City, Utah, 
USA). CS solutions (pH 5.5) were purchased from Hebei 
Taijihuan Nanoproducts (Qinhuangdao, China). DNA-CS 
mixtures were prepared by combining CS solution (pH 5.5) 
and plasmid DNAs at 60°C with a mass ratio of 3:10, fol-
lowed by vortexing for 5 min. 
1.3  Immunization protocol 
As described in previous studies [10], rabbits were divided 
into seven groups, with 18 rabbits in each group. DNA vac-
cine groups: (i) pTpGpd (100 g), (ii) pTpGpd (100 g) 
coated with CS (30 g), (iii) pTpGpd (100 g) and pIL-2 
(100 g), (iv) pIL-2 (100 g) and pTpGpd (100 g) coated 
with CS (30 g) were inoculated in the left hind leg quadri-
ceps of rabbits. Controls included pIL-2 coated with CS, 
pIL-2 and CS. The complete regimen included three im-
munizations administered once every two weeks. Two days 
before injections, 100 L of 0.25% bupivacaine was inject-
ed into the inoculation sites. At week 8 after the first im-
munization, three rabbits from each group were used to de-
termine cytokine measurements and splenocyte proliferation 
assay. 
1.4  Infection and rabbit lesion and ulcer scoring  
At week 10 after the first immunization, 15 rabbits in each 
group were challenged subcutaneously with the Tp Nichols 
strain at eight sites (105 bacteria/site) in the back. Skin le-
sions were observed and measured at the injection sites 
every three days for 60 days. Lesion spirals were investi-
gated by dark-field (DF) and silver staining methods at day 
21 post-Tp challenge. The ratio of the number of 
DF-positive lesions to the total number of the lesions was 
calculated for each group. The ratio of the number of ulcer-
ative lesions to the total number of the lesions was also cal-
culated for each group.  
1.5  Analysis of TpGpd-specific antibody responses by 
ELISA during immunity and infection 
To evaluate anti-Gpd humoral responses during infection,   
1 mL of blood was collected from immunized rabbit ear 
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veins for each group (n=18, 18, 18, 18, 18, 15, 12, 9, 9, 9, 9, 
and 6) at corresponding times (weeks 0, 2, 4, 6, 8, 10, 12, 14, 
20, 24, 28, and 32) after the first immunization, followed by 
centrifugation for isolation of serum. Each well was coated 
with 100 L purified recombinant Gpd protein (50 g mL1) 
overnight at 4°C and incubated with 100 L of serial two- 
fold dilutions of sera for 60 min at 37°C, before the addition 
of 100 L of horseradish peroxidase (HRP)-conjugated goat 
anti-rabbit IgG (1:2000) for 60 min at 37°C and 3,3′,5,5′-      
tetramethylbenzidine (TMB) substrate solution. Each sam-
ple was tested in triplicate and the absorbance was meas-
ured at 450 nm using an automatic ELISA reader (Mul-
tiskan MK-3, Finland). Antibody titers were calculated as 
the highest dilution that gave a positive reading. The cutoff 
value was set as twice the mean absorbance of sera from the 
negative control. 
1.6  Preparation of spleen cell suspensions  
Spleen cells were obtained from three rabbits from each 
group of infected rabbits (n=18, 15, 12, 9, 6 and 3) at cor-
responding times (weeks 8, 10, 12, 14, 30, and 34), as pre-
viously described [10]. Briefly, rabbits were euthanized by 
the air embolism method. Partial spleens were taken and 
incubated in 5 mL of cold D-Hank’s solution. Spleen tissues 
were ground through copper grids (100- to 200-mesh) to 
obtain spleen cell suspensions. After centrifugation for 10 
min at 2100×g, supernatants were discarded and 10 mL of 
red blood cell lysis buffer (139.6 mmol L1 NH4Cl, 16.96 
mmol L1 Tris; pH 7.2) was added, followed by incubation at 
37°C for 10 min. After centrifugation for 10 min at 2100×g, 
supernatants were discarded and the cells resuspended in 
RPMI-1640 medium containing 10% FBS.  
1.7  Detection of cytokines 
IL-2 and IFN- levels of spleen cells were determined ac-
cording to the instructions of the cytokine ELISA detection 
kit. Briefly, spleen cells were added into 96-well plates with 
6×105 cells in each well, followed by incubation at 37°C for 
72 h. Purified protein was used as the stimulating antigen 
(20 g mL1). Samples with concanavalin A (ConA, 10 g 
mL1, Sigma) as the stimulating antigen were used as posi-
tive controls. Samples without stimulating antigens were 
used as negative controls. Supernatants harvested from cul-
tured cells were used immediately or stored at 80°C. 
1.8  Spleen lymphocyte proliferation assays 
Spleen lymphocyte proliferative response was measured 
using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-     
lium bromide (MTT) colorimetric method, as previously 
described [10]. Briefly, spleen cells were seeded at 4×106 
cells mL1 in triplicate in 96-well plates and cultured in 
RPMI-1640 medium (HyClone) with 10% heat-inactivated 
FBS (HyClone), 100 U mL1 penicillin, 100 g mL1 strep-
tomycin, and 2 mmol L1 L-glutamine at 37°C and 5% CO2 
with or without antigen stimulation. Purified protein was 
used as stimulating antigen (10 g mL1). Samples with 
ConA (5 g mL1, Sigma) as stimulating antigen was set as 
positive controls. Samples without stimulating antigens were 
used as negative controls. Following incubation for 68 h,   
20 L MTT (Sigma) was added to each well; plates were 
then incubated for 4 h. At the end of the incubation, plates 
were centrifuged at 1500×g for 8 min and the supernatants 
in each well were removed. One hundred microliters of di-
methylsulfoxide (DMSO) was then added into each well to 
solubilize the formazan precipitates for 10 min under oscil-
lation. The stimulation index (SI) was determined at a 
wavelength of 570 nm, calculated as the ratio of A570 of 
stimulated proliferation to that of unstimulated proliferation. 
1.9  Statistical analyses 
The experimental data, including the absorbance values at 
450 nm of antibodies in sera, levels of IL-2 and IFN- se-
creted by spleen cells, and SI of spleen cells were given as 
mean±standard error (SE). Statistical software (SPSS, ver-
sion 13.0) was used for a two-way analysis of variance with 
a Bonferroni post-hoc test, P<0.05 indicated a significant 
difference. The ratio of the number of DF-positive lesions 
and ulcerative lesions to the total number of the lesions 
were calculated for each group, which was used for 2 tests. 
P<0.05 indicated a significant difference. 
2  Results 
2.1  Expression of Gpd or IL-2-encoding gene in HeLa 
cells 
The plasmids, pTpGpd and pIL-2, were transfected into 
HeLa cells. After 48 h, the total proteins were harvested. 
Transient expression of TpGpd and IL-2 were examined by 
immunoblotting. The present study confirmed that cells 
transfected with these plasmids expressed the corresponding 
proteins, based on the predicted molecular masses for Gpd 
(~41 kD) and IL-2 (~22 kD) (data not shown), as previously 
described [10,11]. 
2.2  TpGpd antibody levels increased when DNA vac-
cines were coated with CS or co-inoculated with pIL-2 
during immunization and infection 
At weeks 0, 2, 4, 6, 8, 10 (Tp challenge), 12, 14, 20, 24, 28, 
and 32 after the first immunization, blood was obtained 
from rabbits and the anti-TpGpd special antibody levels 
were determined by ELISA. The ELISA results indicated 
that pTpGpd induced an increase in the anti-TpGpd antibody 
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levels from week 2, when compared with the pIL-2 coated 
with CS, pIL-2 alone or CS immunized rabbits (Figure 1). 
CS vectoring (0.87, 1.07 and 1.18 at weeks 4, 6 and 8, re-
spectively) and coadministration of pIL-2 (1.37, 1.66 and 
1.69 at weeks 4, 6 and 8, respectively) adjuvanted pTpGpd 
(0.54, 0.82 and 0.84 at weeks 4, 6 and 8, respectively) as 
evidenced by the week 4 ,6 and 8 antibody titers (P<0.05). 
The combination of CS vectoring and pIL-2 resulted in the 
highest anti-TpGpd antibody levels achieved (1.46, 1.75 and 
1.78 at weeks 4, 6 and 8 respectively, P<0.05). However, 
there was no significant difference (P>0.05) observed in 
rabbits when administered with pTpGpd coated with CS 
(0.87, 1.07 and 1.18 at week 4, 6 and 8, respectively) com-
pared with the pTpGpd alone (0.54, 0.82 and 0.84 at weeks 4, 
6 and 8, respectively). 
During the infection period (weeks 1032), vaccine 
groups (CS+pTpGpd+pIL-2 group, pTpGpd +pIL-2 group 
and the CS+ pTpGpd group) maintained stable and signifi-
cantly higher levels of anti-TpGpd IgG antibodies compared 
with the respective negative controls (pIL-2+CS, pIL-2 
alone and CS groups; P<0.05) (Figure 2). 
2.3  The measurements of cytokine levels of IL-2 and 
IFN- 
Rabbit spleen cells were collected and cultured at week 8. 
The IL-2 and IFN- levels in the supernatants harvested 
from the cultured cells were determined by ELISA. As 
shown in Figure 3, pTpGpd induced a significant increase in  
 
 
Figure 1  Absorbance values indicating IgG antibody levels induced by 
TpGpd vaccines adjuvanted with pIL-2 adsorbed to CS during immuniza-
tion. Groups of rabbits (n=18) were immunized with DNA vaccines 
pTpGpd (100 g), pTpGpd coated with CS (30 g) (CS+pTpGpd), 
pTpGpd and pIL-2 (100 µg) (pTpGpd+pIL-2), pTpGpd and pIL-2 coated 
with CS(CS+pTpGpd+pIL-2) at 0, 2 and 4 weeks, pIL-2 adsorbed to 
CS-immunized rabbits(CS+pIL-2), pIL-2 alone and CS-immunized rabbits 
(CS) were used as negative controls. TpGpd DNA vaccines adsorbed to CS 
were inoculated into the left hind leg quadriceps of rabbits Blood was 
drawn from ear veins at 0, 2, 4, 6, and 8 weeks post-immunization. The 
anti-TpGpd antibody levels from sera were determined by indirect ELISA. 
A450, optical density at 450 nm. 
 
Figure 2  Absorbance values indicating IgG antibody levels induced by 
TpGpd vaccines adjuvanted with pIL-2 wrapped with CS during infection. 
The groups of rabbits are as in Figure 1. At week 10 after the first immun-
ization, 15 of 18 rabbits in each group were challenged intradermally at 
eight sites on the back with 105 T. pallidum (Nichols) spirochetes. Blood 
was drawn from ear veins at 10 (Tp challenge), 12, 14, 20, 24, 28 and 32 
weeks post-immunization. The anti-TpGpd antibody levels from sera were 
determined by indirect ELISA. A450, optical density at 450 nm. 
 
 
Figure 3  Levels of IL-2 and IFN- secreted by spleen cells in rabbits with 
TpGpd stimulations. The groups of rabbits are as in Figure 1. Two weeks 
after the final immunization (week 8), rabbits (three per group) were sacri-
ficed and the splenocytes isolated. Splenocytes were then stimulated with 
Gpd at 20 g mL1 for 3 d. The experiment was repeated with similar re-
sults; values are shown as means±SE. 
the IL-2 (110.3) and IFN- (224.8) levels, when compared 
with the IL-2 and IFN- levels of the pIL-2+CS (IL-2, 57.6; 
IFN-, 67.7), pIL-2 (IL-2, 54.4; IFN-, 64.2) or CS (IL-2, 
22.8; IFN-, 20.7) control groups, respectively. Administra-
tion with pTpGpd+CS did not significantly affect the IL-2 
(pTpGpd+CS, 122.2; pTpGpd, 110.3) and IFN- levels 
(pTpGpd+CS, 249.4; pTpGpd, 224.8) induced by TpGpd, 
while pTpGpd+pIL-2 resulted in an increase of IL-2 
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(pTpGpd+pIL-2, 173.4; pTpGpd, 110.3; P<0.05) and IFN- 
level (pTpGpd+pIL-2, 442.3; pTpGpd, 224.8; P<0.05) in-
duced by TpGpd.  
2.4  T-cell proliferation is stimulated by pTpGpd and 
pIL-2 during immunization and infection 
At weeks 8, 10 (Tp challenge), 12, 14, 30, and 32 after the 
first immunization, rabbit spleen cells were collected and 
proliferation of T cells were determined by the MTT method. 
As shown in Table 1, pTpGpd induced significant prolifera-
tion of T cells, when compared with the levels of the pIL-2 
coated with CS, pIL-2 and CS (30 g) control groups, re-
spectively (P<0.05). pTpGpd+CS alone did not significantly 
affect the stimulation induced by TpGpd at week 8 (pTpGpd+ 
CS, 3.34; pTpGpd, 2.88; P>0.05), while pTpGpd+    
pIL-2 resulted in increased stimulation induced by TpGpd 
(pTpGpd+pIL-2, 4.52; pTpGpd, 2.88; P<0.05). Combina-
tion of CS vectored pTpGpd and pIL-2 led to the most ele-
vated T-cell proliferation stimulation level (4.96, P<0.05). 
During the infection period (0–168 d), all vaccine groups 
maintained stable and significantly higher levels of T-cell 
proliferation stimulation compared with the respective neg-
ative controls (pIL-2+CS, pIL-2 alone and CS groups; 
P<0.05). 
2.5  Determination of the protective effect of pTpGpd 
based DNA vaccines from Tp infection 
At week 10 after the first immunization, 15 of the 18 rabbits 
in each group were challenged with the Tp Nichols strain. 
Skin lesions were observed and measured in the infected 
sites every three days. Lesion spirals were investigated by 
dark-field and silver staining methods 21 days after Tp in-
fection. As shown in Table 2, ratios of positive skin lesions 
and ulcer lesions in groups immunized with pTpGpd were 
significantly lower than those of the pIL-2+CS, pIL-2, or CS 
groups (P<0.001), demonstrating that pTpGpd elicits sig-
nificant protection against the Tp challenge. Co-administra-     
tion of pIL-2 with pTpGpd conferred superior protection (the 
positive skin lesions and ulcer lesions observed were 
11.67% and 10.00%, respectively) to CS vectored pTpGpd 
(the positive skin lesions and ulcer lesions observed were 
25.00% and 40.00%, respectively). In addition, the presence 
of both pIL-2 and CS with pTpGpd led to the greatest level of 
protection whereby the positive skin lesions and ulcer le-
sions observed were 8.33% and 4.17%, respectively 
(P<0.05). 
The lesions in rabbits immunized with CS+pTpGpd+    
pIL-2 were the smallest, least indurated, and quickest to heal 
(42 d) (Figure 4); intermediate results were seen with the 
lesions on rabbits immunized with CS+pTpGpd or pTpGpd+ 
Table 1  Stimulation index (SI) of spleen cells at corresponding times during immunization and infectiona) 
Group 
Days (weeks) 

















CS   0.65±0.28d 0.57±0.23 1.21±0.42 1.44±0.45 1.23±0.45 1.52±0.37 
pIL-2 0.85±0.24 0.83±0.33 1.22±0.44 1.56±0.54 1.27±0.46 1.54±0.37 
pIL-2+CS 0.84±0.36 0.88±0.32 1.28±0.43 1.68±0.57 1.32±0.36 1.58±0.44 
pTpGpd  2.88±0.21 2.84±0.32 3.14±0.46 3.47±0.52 3.24±0.34 3.32±0.44 
pTpGpd+CS 3.34±0.46 3.28±0.55 3.58±0.63 3.88±0.38 3.62±0.44 3.60±0.47 
pTpGpd+pIL-2 4.52±0.47 4.54±0.56 4.84±0.49 4.98±0.65 4.73±0.38 4.68±0.47 
pTpGpd+pIL-2+CS 4.86±0.38 4.82±0.46 4.97±0.53 5.17±0.55 4.92±0.47 4.88±0.62 
a) The groups are as in Figure 1. a, The 0, 14, 28, 140 and 168 days post-infection; b, at week 8, 10, 12, 14, 30 and 32 after the first immunization; c, 
three rabbits per group were sacrificed and the splenocytes were isolated for test at different times; d, mean±SE. 
Table 2  Ratio of DF-positive skin lesion number to the total lesion number and ratio of ulcer lesion number to the total lesion number in each group after 
Tp challengea) 
Group Rabbit number 
Number of DF-positive lesions/total number of 
lesions (%) 
Number of ulcerative lesions/total number of 
lesions (%) 
CS  15 115/120 (95.83) 112/120 (93.33) 
pIL-2 15 107/120 (89.17) 104/120 (86.67) 
pIL-2 +CS 15 105/120 (87.50) 100/120 (83.33) 
pTpGpd 15 30/120 (25.00) 45/120 (37.50) 
pTpGpd+CS 15 30/120 (25.00) 48/120 (40.00) 
pTpGpd+pIL-2 15 14/120 (11.67) 12/120 (10.00) 
pTpGpd+IL-2+CS 15 10/120 (8.33) 5/120 (4.17) 
a) The groups are as in Figure 1. DF, dark-field. 
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Figure 4  Measurements of erythematous lesions from groups of 15 rab-
bits infected with T. pallidum post-challenge (week 10) at three-day inter-
vals (0–60 d). The groups of rabbits are as in Figure 1. At week 10 after 
pTpGpd DNA vaccination, 15 of 18 rabbits in each group were challenged 
intradermally at eight sites on the back with 105 T. pallidum (Nichols) 
spirochetes. Each bar represents the mean±SE of diameters of erythema-
tous lesions from 15 rabbits per group.  
pIL-2; and the immunized control rabbits had the largest, 
most ulcerative and indurated lesions that did not heal dur-
ing the 60-day observation period. Erythema at the chal-
lenge sites was apparent on rabbits immunized with DNA 
vaccines within 2–3 days post-challenge, whereas those 
immunized with CS+ pIL-2/CS control rabbits did not de-
velop any signs at the challenge sites until approximately 
6–9 days after the challenge.  
3  Discussion 
A significant drawback of DNA vaccines is its nature as a 
bacterial plasmid, which is able to express its protein prod-
uct in eukaryotic cells but cannot replicate. The efficiency 
of a DNA vaccine is limited by the uptake of the plasmid 
passively into tissue cells or other inflammatory cells. Thus, 
large doses of plasmid DNA were needed in order to obtain 
an effective immune response. CS is the only natural poly-
mer of alkaline amino-polysaccharide that is deacetylated 
from chitin, with good biological absorption and compati-
bility. A protective effect of different molecular weights and 
concentrations of chitosan particles has been demonstrated 
against the destruction of foreign DNA by intracellular ly-
sosomes [12]. Li et al. [1] showed that the CS wrapped gene 
significantly improved gene transfection efficiency and 
prolonged the expression of DNA in mammalian cells. Ad-
ditionally, CS nanoparticles of cytokine genes significantly 
improved the immune effect in mice through oral or subcu-
taneous immunization [3–5]. 
Early studies indicated that CS nanoparticles could be 
used as a gene transduction vector and pIL-2 as adjuvant, in 
order to enhance immune response of pTp92 single-gene 
DNA vaccine [10]. This previous study showed that pIL-2 
gene adjuvant could significantly enhance the immune re-
sponse effects of pTp92 single-gene DNA vaccine; however, 
the adjuvant effect of CS nanoparticles was not obvious. 
Building upon this previous study, the current study further 
validated the immune response of TpGpd DNA vaccine 
adjuvanted with IL-2 coated with CS compared with Tp92 
DNA vaccine adjuvanted with IL-2 and CS. At the same 
time, we also assessed the immune response of TpGpd 
DNA adjuvanted with IL-2 and coated with CS at different 
periods before and after Tp infect rabbit skin to evaluate 
protective efficacy of anti-Tp skin infections. It was shown 
that compared with vaccine group (pTpGpd+pIL-2 com-
bined vaccine group, pTpGpd vaccine group), the vaccine 
coated with CS nanoparticles group (CS+pTpGpd+pIL-2 
combined vaccine group and CS+pTpGpd vaccine group) 
showed slightly increased TpGpd specific antibody level, 
splenocyte proliferation level and IL-2 cytokine stimulation 
level, despite not being statistically significant. 
The current study revealed that CS nanoparticles promote 
the humoral and cellular immunity of the pTpGpd vaccine. 
This further supports our previous reports [10], indicating 
that CS nanoparticles increase exogenous genes into the 
cells, but there was no positive relationship between the 
number of exogenous genes in the cells and intracellular 
gene expression [13]. It was shown that aside from the sta-
bility of the exogenous gene (including protection from the 
DNA enzyme degradation in vivo), CS is important for effi-
cient translocation to nucleus [14]. Moreover, the size and 
quantity of electric charge of CS-DNA complexes also con-
tribute to translocation to the nucleus [15]. It has been 
shown that the bigger the size of transfected DNA, the more 
difficult translocation to the nucleus is. In this study, we 
coated a DNA vaccine with CS nanoparticles with an aver-
age size around 300–500 nm, and this small size may have 
led to the successful adjuvant effect.  
Given our previous report [16] and results of the 
pTpGpd+pIL-2 combined vaccine group and pTpGpd vac-
cine group, a vaccine with (pcD/Gpd-IL-2) or without 
(pTpGpd+pIL-2) fusion of IL-2 and TpGpdhad was im-
proved immune response during infection. Analysis of skin 
lesions, ulcer incidence and swelling during Tp skin infec-
tion (0–60 d) indicated that the anti-Tp protection of 
CS+pTpGpd+pIL-2 combined vaccine group showed the 
best results. However, compared with the vaccine group 
(pTpGpd+pIL-2 combined vaccine group and the pTpGpd 
vaccine group) and vaccine wrapped by CS nanoparticles 
group (CS+pTpGpd+pIL-2 combined vaccine group and 
CS+pTpGpd vaccine group), CS nanoparticles only slightly 
promoted the immune response without statistical signifi-
cance. 
In summary, this study demonstrates that all vaccine 
groups induced humoral and cellular immunity by intra-
muscular injection. Additionally, the pIL-2 adjuvant signif-
icantly enhanced the pTpGpd vaccine to induce the produc-
180 Zhao F J, et al.   Sci China Life Sci   February (2013) Vol.56 No.2 
tion of higher, longer term and stable levels of antibodies 
and spleen cell proliferation during immunity and infection. 
However, vaccines coated with CS nanoparticles did not 
show a significant promotion of the immune response as in 
other reports. For the protection of skin infection during 
early stage syphilis infection, the combined regimen of 
pTpGpd, CS, and pIL-2 achieved the best protection. How-
ever, further studies are needed to determine methods for 
complete protection and to address the insufficiency effect 
of CS. 
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